Press Releases

Date Title and Summary Additional Formats
Toggle Summary Mylan Reports First Quarter 2018 Results and Reaffirms 2018 Guidance
HERTFORDSHIRE , England and PITTSBURGH , May 9, 2018 /PRNewswire/ --  Mylan N.V. (NASDAQ: MYL) today announced its financial results for the three months ended March 31, 2018. First Quarter 2018 Financial Highlights Total revenues of $2.68 billion , down 1% compared to the prior year period.
View HTML
Toggle Summary Mylan to Release First Quarter 2018 Financial Results on May 9, 2018
HERTFORDSHIRE, England and PITTSBURGH , May 2, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced that it will release its first quarter 2018 financial results, on Wed., May 9 , before the open of the U.S. financial markets.  The company also will host a
View HTML
Toggle Summary Mylan Adds to Growing Women's Healthcare Portfolio with Launch of Generic for Oral Contraceptive Yaz®
HERTFORDSHIRE, England and PITTSBURGH , April 25, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the U.S. launch of Drospirenone and Ethinyl Estradiol Tablets USP, 3 mg/0.02 mg, a generic version of Bayer's Yaz ® Tablets.
View HTML
Toggle Summary Mylan Presents Equivalence Data on Glatiramer Acetate Compared to Copaxone® at American Academy of Neurology 70th Annual Meeting
Three posters highlight Mylan's rigorous Glatiramer Acetate development program HERTFORDSHIRE, England , and PITTSBURGH , April 21, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced three scientific abstracts from the Glatiramer Acetate development program
View HTML
Toggle Summary Mylan Provides Statement in Response to Reuters Article, “Mylan seeks deal for German Merck's consumer products unit: sources,” Dated April 13, 2018
Although it’s Mylan’s policy to not comment on rumors or speculation, given the egregious inaccuracy of reports issued this morning, the company is compelled to confirm that the Reuters article is untrue.
View HTML
Toggle Summary Investor Day Highlights Durability of Mylan's Global Platform
Management details progress on complex scientific programs and commercial diversification; reaffirms 2018 guidance Company is built to last and positioned for growth HERTFORDSHIRE, England and PITTSBURGH , April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.
View HTML
Toggle Summary Mylan to Leverage its World-Class Scientific Platform to Develop a Novel Delivery for Meloxicam, a Non-Opioid Pain Medication
Mylan acquires global development and marketing rights from Prayog Labs Once approved, the product could potentially offer a fast-acting, non-addictive treatment for acute pain HERTFORDSHIRE, England and PITTSBURGH , April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V.
View HTML
Toggle Summary Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab)
Mylan acquires exclusive license to commercialize in Europe HERTFORDSHIRE, England and PITTSBURGH , April 11, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced it is partnering with Fujifilm Kyowa Kirin Biologics Co., Ltd.
View HTML
Toggle Summary Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis Mapi Pharma has completed an open-label Phase II clinical trial and is preparing to commence a pivotal Phase III clinical trial to support marketing applications
View HTML
Toggle Summary Mylan Strengthens Its Capital Structure by Extending Its Debt Maturities with a Successful $1.5 Billion Bond Offering
HERTFORDSHIRE, England and PITTSBURGH , April 6, 2018 /PRNewswire/ -- Global pharmaceutical company Mylan N.V. (NASDAQ: MYL) today announced the pricing of a private offering of $1.5 billion aggregate principal amount of senior notes on March 28, 2018 , comprised of: $750 million aggregate
View HTML